CN111991662B - Intelligent system for automatically providing oxygen treatment scheme - Google Patents
Intelligent system for automatically providing oxygen treatment scheme Download PDFInfo
- Publication number
- CN111991662B CN111991662B CN202010958090.0A CN202010958090A CN111991662B CN 111991662 B CN111991662 B CN 111991662B CN 202010958090 A CN202010958090 A CN 202010958090A CN 111991662 B CN111991662 B CN 111991662B
- Authority
- CN
- China
- Prior art keywords
- value
- flow
- oxygen
- tcs
- carbon dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/02—Total factory control, e.g. smart factories, flexible manufacturing systems [FMS] or integrated manufacturing systems [IMS]
Abstract
The invention relates to medical equipment, in particular to an intelligent system for automatically providing an oxygen treatment scheme, which mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end expiration (PETCO 2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a human-computer interaction interface and a communication transmission unit. The method automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value, an absorption flow correction interval, a flow correction interval and an output flow, so that the dynamic percutaneous blood oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO 2) interval value, the percutaneous oxygen partial pressure (tcpO 2) interval value and the percutaneous carbon dioxide partial pressure (tcpCO 2) interval value of a patient are accurately controlled within a reasonable target percutaneous blood oxygen saturation (tcs 02) control interval value, and the effectiveness and safety of oxygen therapy are improved.
Description
Technical Field
The invention relates to medical equipment, in particular to an intelligent system for automatically providing an oxygen treatment scheme.
Background
Oxygen inhalation therapy (abbreviated as "oxygen therapy") is one of the most commonly used rescue or treatment means in hospitals, and aims to improve the anoxic state of the body by inhaling oxygen to the patient. At present, the oxygen therapy is understood to be shallow in China, the whole oxygen therapy process lacks strict monitoring and necessary flow adjustment measures, a specific oxygen therapy target blood oxygen value is not given, the oxygen deficiency type of a patient is difficult to discover in time, and systematic oxygen therapy measures cannot be carried out.
The general basic vital signs at present are body temperature, pulse, respiration, blood pressure, blood oxygen saturation and carbon dioxide end-expiration PETCO2, wherein the blood oxygen saturation and the carbon dioxide end-expiration PETCO2 are suggested as a fifth vital sign and a sixth vital sign (british chest department (BTS) emergency oxygen therapy guideline (2008 edition)), and the intelligent oxygen therapy system with the target blood oxygen saturation as a control point is currently marketed, but the method for adjusting the oxygen flow by only taking the blood oxygen saturation as a parameter has obvious defects: 1. whether the patient has carbon dioxide retention cannot be judged only by the blood oxygen saturation value, and reasonable oxygen therapy orders and initial oxygen flow cannot be given; 2. when the patient's condition progresses, carbon dioxide retention occurs and the blood oxygen saturation decreases, if the initial flow is a medium flow, the flow is adjusted to be at most 4L/min, and the patient can suffer from oxygen poisoning symptoms or even coma and death. 3. When the illness state of a patient is progressively aggravated, the oxygen saturation degree of blood is monitored independently, the anoxic type of the stage of the patient cannot be rapidly and accurately distinguished, and the oxygen therapy scheme cannot be timely adjusted, so that double monitoring with a percutaneous oxygen saturation degree (TcSO 2) monitoring unit and a carbon dioxide end expiration (PETCO 2) monitoring unit is adopted, and the anoxic type is rapidly distinguished by combining other vital signs of the patient, so that the real safe oxygen therapy, the controlled oxygen therapy and the intelligent oxygen therapy can be achieved by rapidly adjusting the oxygen therapy scheme.
Disclosure of Invention
In view of the above-mentioned drawbacks in the background art, the present invention provides an intelligent system for automatically providing an oxygen therapy regimen, which overcomes the shortcomings of the prior art.
The technical scheme of the invention is realized as follows:
an intelligent system for automatically providing an oxygen therapy regimen, comprising: the system mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end expiration (PETCO 2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a man-machine interaction interface and a communication transmission unit, wherein a control data model is arranged in the data model analysis control unit, and analysis control data model construction elements comprise, but are not limited to, an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide end expiration (PETCO 2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index); presetting a specific data model of an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a target end-tidal carbon dioxide (PETCO 2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index) in a data model analysis control unit, wherein the percutaneous blood oxygen saturation (tcs 02) value, the percutaneous blood oxygen saturation (tcs 02) allowable deviation value, the percutaneous blood oxygen saturation (tcs 02) interval value, the end-tidal carbon dioxide (PETCO 2) interval value, the initial flow value and the oxygen inhalation time length can be personalized at a human-computer interaction interface according to the state of a patient; the human-computer interaction interface at least comprises a target percutaneous blood oxygen saturation (tcs 02) setting key (or a touch screen key), a carbon dioxide end expiration (PETCO 2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key) and an oxygen therapy scheme selection key (or a touch screen key),
furthermore, the percutaneous blood oxygen saturation (tcs 02) interval value and the end-tidal carbon dioxide (PETCO 2) interval value are preset into a data model analysis control unit, the oxygen therapy scheme and the recommended blood oxygen saturation interval value and oxygen inhalation flow correction interval value are provided, and a reasonable oxygen therapy scheme is set and selected on a human-computer interaction interface; the flow correction interval is divided into three adjustment intervals, namely a low flow area, a medium flow area and a high flow area, the flow correction interval value is arranged in the data model, and as long as an initial flow value is set on a human-computer interaction interface, a reasonable oxygen treatment scheme is selected, and the data model analysis control unit automatically matches the corresponding flow correction interval and a percutaneous blood oxygen saturation (tcs 02) interval value;
the data model analysis control unit is internally provided with a three-level oxygen therapy scheme, wherein the end-tidal carbon dioxide (PETCO 2) value is normal, and the primary oxygen therapy scheme is started when the end-tidal carbon dioxide (PETCO 2) value is not low, the secondary oxygen therapy scheme is started when the end-tidal carbon dioxide value is abnormal and is higher than 6kpa (45 mmhg), and the three-level oxygen therapy scheme is started when a patient has low perfusion symptoms by pressing a low perfusion mode key (or a touch screen key), so that the percutaneous blood oxygen saturation (tcs 02) monitoring unit and the end-tidal carbon dioxide (PETCO 2) monitoring unit are used for continuously monitoring the dynamic percutaneous blood oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO 2) value of the patient;
1. if the end-tidal carbon dioxide (PETCO 2) value is normal, 4.6kpa (35 mmhg) is less than or equal to Petco2 is less than or equal to 6kpa (45 mmhg), the percutaneous blood oxygen saturation (tcs 02) value is less than or equal to 94%, the system judges that the patient is hypo-stretch hypoxia without hypercapnia, and when the primary oxygen treatment scheme is adopted, when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is stably kept within the control interval value of the patient, the initial flow is maintained; when the dynamic percutaneous blood oxygen saturation (tcs 02) value exceeds the upper limit of the control interval value and reaches the intervention time, the flow rate automatically gradient decreases; when the dynamic percutaneous blood oxygen saturation (tcs 02) value is lower than the lower limit of the control interval value and reaches intervention time, the flow is automatically increased in a gradient manner, so that the dynamic percutaneous blood oxygen saturation (tcs 02) value of a patient is stably maintained in the control interval value, and the aim of accurately controlling oxygen therapy is fulfilled; when the oxygen output is regulated to the maximum value or the minimum value and is kept for 30min, but the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient still deviates from the control interval value, the data model analysis control unit gives out warning information and a recommended oxygen therapy scheme, medical staff confirms and then executes the recommended oxygen therapy scheme, the medical staff can also manually set the warning information, the warning information can be prompted on a human-computer interaction interface, can be displayed on a clinical monitoring terminal and can also be displayed simultaneously;
2. when the end-tidal carbon dioxide (PETCO 2) value exceeds a critical value of more than 6kpa (45 mmhg), the percutaneous blood oxygen saturation (tcs 02) value is less than or equal to 94%, and the system judges that the patient is anoxic with hypercarbonated blood and automatically switches into a secondary oxygen treatment scheme taking the end-tidal carbon dioxide (PETCO 2) value as the dominant one; the flow correction interval is adjusted to be a low flow area;
3. if the patient has microcirculation disturbance such as heart failure, myocardial infarction, shock and other hypo-perfusion symptoms, the three-stage oxygen treatment scheme is manually selected:
a. if the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), whether the percutaneous oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) with hypercarbonated blood, and the flow correction interval is adjusted to be a low flow area;
b. during periods when the percutaneous blood oxygen saturation (tcs 02) value stabilizes > 90% and the end-tidal carbon dioxide (petoc 2) value stabilizes < 6kpa (45 mmhg), the system automatically selects an oxygen treatment regimen for which the histological hypoxia (or circulatory hypoxia) is not accompanied by hypercapnia; the flow correction interval is adjusted to be a low flow area;
c. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the 4.6kpa (35 mmhg) < end-tidal carbon dioxide (PETCO 2) value is less than 6kpa (45 mmhg), the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) and hypo-stretch hypoxia without hypercarbonated blood, and the flow correction interval is adjusted to be a medium flow area;
d. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), and the state is stably maintained for 1-5 min, the system automatically selects an oxygen therapy scheme flow correction interval of tissue hypoxia (or cyclic hypoxia) and hypotonic hypoxia with hypercarbonated blood is adjusted to a low flow area or automatically restores the output flow value to an initial flow value which is originally set, the automatic intervention and adjustment of the output flow are stopped, a data model analysis control unit gives warning information to prompt medical staff to correct the oxygen therapy scheme, and the warning information is prompted on a human-computer interaction interface or remotely transmitted to a clinical monitoring terminal;
4. the blood-type anoxic mode is built in the data model analysis control unit, and is set as medium-flow oxygen therapy (doctor's advice flow value is 3L/min-4L/min), the flow correction interval is defined as 0.1L/min-4L/min, and the blood-type anoxic blood gas change is special, but the blood-type anoxic blood gas change is easy to judge clinically, and only a nursing staff needs to select the mode when the blood-type anoxic oxygen therapy device is used;
5. the data model analysis control unit is internally provided with a neonate mode, and is set to be low-flow oxygen therapy (the doctor's advice flow value is between 0.5L/min and 2L/min), and the flow correction interval is defined to be between 0.1L/min and 2L/min;
6. when the end-tidal carbon dioxide (PETCO 2) value is lower than a critical value less than 4.6kpa (35 mmhg), the gradient is regulated to the highest value of the interval flow, if the initial flow interval is a low flow area, the interval flow is automatically regulated to be a medium flow area; or stopping automatic intervention to regulate the output flow, giving out warning information by the data model analysis control unit, prompting medical staff to correct the oxygen treatment scheme, and prompting or remotely transmitting the warning information to the clinical monitoring terminal on the human-computer interaction interface;
during oxygen therapy, if the percutaneous blood oxygen saturation (tcs 02) monitoring unit and the end-tidal carbon dioxide (PETCO 2) monitoring unit work abnormally, the monitoring unit comprises and is not limited to the falling of a probe from a monitoring part, the damage of the probe and the incapability of normally acquiring blood oxygen values, the sampling tube is blocked or distorted by secretion, the data model analysis control unit automatically restores the output flow value to an initial flow value which is originally set, the automatic intervention regulation of the output flow is stopped, potential safety hazards are avoided, and warning information is sent to prompt medical staff to check.
Further, a data model analysis control unit of a percutaneous blood oxygen saturation (tcs 02) monitoring unit and a carbon dioxide at end expiration (PETCO 2) monitoring unit is established, the current hypoxia type of a patient is intelligently judged, whether carbon dioxide retention exists or not is intelligently judged, a reasonable oxygen treatment scheme, a suggested blood oxygen saturation interval value and an oxygen absorption flow correction interval value are selected, and medical staff only need to select a reasonable oxygen treatment scheme on a human-computer interaction interface; the initial oxygen flow and the oxygen treatment duration are enough, and when the disease state progresses, the oxygen treatment scheme adjustment suggestion can be automatically provided, and meanwhile, the warning information is sent out to prompt medical staff to correct the oxygen treatment scheme, and the warning information is prompted on a human-computer interaction interface or remotely transmitted to a clinical monitoring terminal.
Further, an electronic encoder is adopted as a target percutaneous blood oxygen saturation (tcs 02) value setting key (or a touch screen key), a carbon dioxide end expiration (PETCO 2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key) and an oxygen therapy scheme selecting key; virtual keys may also be provided on the microcomputer touch screen.
Further, the data model analysis control unit takes the personalized target percutaneous oxygen saturation (tcs 02) value, end-tidal carbon dioxide (PETCO 2) value and oxygen therapy scheme selection key as a three-stage control unit, the given target percutaneous oxygen saturation (tcs 02) value is provided with an allowable deviation value, and the target percutaneous oxygen saturation (tcs 02) is allowableDeviation value is at+1%～+Defined between 3%; the end-tidal carbon dioxide (PETCO 2) values given have interval values of 4.6kpa (35 mmhg) < end-tidal carbon dioxide (PETCO 2) values < 6kpa (45 mmhg).
Further, controlling the intervention time to be set between 0 and 60 minutes; preferably, the intervention time is calculated based on the stable time of the dynamic percutaneous blood oxygen saturation (tcs 02) value and the end carbon dioxide (PETCO 2) interval value, when the dynamic percutaneous blood oxygen saturation (tcs 02) value exceeds the control interval value and the state is stably maintained for 1-5 min, the data model analysis control unit reduces the oxygen output flow, when the dynamic percutaneous blood oxygen saturation (tcs 02) value is lower than the target percutaneous blood oxygen saturation (tcs 02) control interval value and the state is stably maintained for 0.5-3 min, the data model analysis control unit increases the oxygen output flow, and when the end carbon dioxide (PETCO 2) interval value exceeds the control interval value and the state is stably maintained for 10min, the oxygen therapy scheme of the hypoxia-associated hypercarbonated blood is switched.
Further, when the end-tidal carbon dioxide (PETCO 2) value is normal, 4.6kpa (35 mmhg) is less than or equal to Petco2 is less than or equal to 6kpa (45 mmhg), the percutaneous blood oxygen saturation (tcs 02) value is less than or equal to 94%, the system judges that the patient is hypo-anoxia and does not accompany hypercarbonated blood, the data model analysis control unit automatically matches the corresponding flow correction interval and blood oxygen saturation interval value according to the set initial flow value and the selected oxygen treatment scheme, and the data model analysis control unit strictly controls the upper limit and the lower limit of the output flow in the flow correction interval when the intervention oxygen output flow is automatically regulated, and the breakthrough is avoided during the automatic regulation.
Further, when the end-tidal carbon dioxide (PETCO 2) value is > 6kpa (45 mmhg) and the state is stable for 5min, the system judges that the patient is hypo-hypoxic with hypercarbonemia, such as the initial flow is in the medium flow or high flow area, the flow gradient is adjusted to 2L/min, such as the initial flow is in the low flow area, the flow gradient is adjusted to 0.5L/min.
Further, if the patient has microcirculation disturbance such as heart failure, myocardial infarction, shock and other low perfusion symptoms, the three-stage oxygen treatment scheme is manually selected:
a. if the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), whether the percutaneous oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) with hypercarbonated blood, and the flow correction interval is adjusted to be a low flow area;
b. during periods when the percutaneous blood oxygen saturation (tcs 02) value is stable by more than 90% and the end-tidal carbon dioxide (PETCO 2) value is stable by less than 6kpa (45 mmhg), the system automatically selects an oxygen treatment scheme of the tissue hypoxia (or circulatory hypoxia) without the hypercapnia, and the flow correction interval is adjusted to be a low flow area;
c. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the 4.6kpa (35 mmhg) < end-tidal carbon dioxide (PETCO 2) value is less than 6kpa (45 mmhg), the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) and hypo-stretch hypoxia without hypercarbonated blood, and the flow correction interval is adjusted to be a medium flow area;
d. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), and the state is stably maintained for 1-5 min, the system automatically selects an oxygen therapy scheme flow correction interval of tissue hypoxia (or cyclic hypoxia) and low-tension hypoxia with hypercarbonated blood, adjusts the flow correction interval to a low flow area or automatically restores the output flow value to an initial flow value which is originally set, the automatic intervention and adjustment of the output flow is stopped, the data model analysis control unit gives warning information to prompt medical staff to correct the oxygen therapy scheme, and the warning information is prompted on a human-computer interaction interface or remotely transmitted to a clinical monitoring terminal.
Furthermore, the blood hypoxia mode is built in the data model analysis control unit, the medium flow oxygen therapy (doctor's advice flow value 3L/min-4L/min) is set, the flow correction interval is defined as 0.1L/min-4L/min, and the blood hypoxia blood gas change is special, but the blood hypoxia blood gas change is easy to judge clinically, and only a nursing staff needs to select the mode when the blood hypoxia oxygen therapy device is used.
Furthermore, a neonate mode is built in the data model analysis control unit, the data model analysis control unit is set to be used for low-flow oxygen therapy (the doctor's advice flow value is between 0.5L/min and 2L/min), and the flow correction interval is defined to be between 0.1L/min and 2L/min.
Furthermore, when the end-tidal carbon dioxide (PETCO 2) value is lower than a critical value less than 4.6kpa (35 mmhg), the gradient is regulated to the highest value of the interval flow, if the initial flow interval is a low flow area, the interval flow is automatically regulated to a middle flow area, or the automatic intervention regulation output flow is stopped, the data model analysis control unit gives out warning information to prompt medical staff to correct the oxygen therapy scheme, and the warning information is prompted on a man-machine interaction interface or remotely transmitted to a clinical monitoring terminal.
Further, the flow correction interval is divided into three adjustment intervals of a low flow area, a medium flow area and a high flow area, and specifically comprises the following steps: the flow correction interval is defined as 0.1L/min-2L/min during low-flow oxygen therapy (doctor's advice flow value is between 0.5L/min and 2L/min), 0.1L/min-4L/min during medium-flow oxygen therapy (doctor's advice flow value is between 3L/min and 4L/min), 5L/min-8L/min during high-flow oxygen therapy (doctor's advice flow value is between 0.1L/min and 8L/min).
Further, the flow correction gradient is a flow value which is increased or decreased every time the flow is adjusted during the intervention flow adjustment, and the flow correction gradient is defined as between 0.1L/min and 1L/min in a defined oxygen flow correction interval.
Further, the parameter setting range of each construction element of the control data model of the data model analysis control unit is preferably such that the allowable deviation value is set to be the target percutaneous blood oxygen saturation (tcs 02) in which the control data model is preset+1, intervention time, definition according to 3min when reducing flow rate, definition according to 0.5min when increasing flow rate; the flow correction interval is defined as 0.5L/min-2L/min in low-flow oxygen therapy (0.5L/min-2L/min), 1L/min-4L/min in medium-flow oxygen therapy (3L/min-4L/min) and 1L/min-8L/min in high-flow oxygen therapy (5L/min-8L/min); the flow correction gradient is 0.5L/min; the target percutaneous blood oxygen saturation (tcs 02) value, the initial flow value and the oxygen treatment duration are set in a personalized way on a human-computer interaction interface according to the individual difference of the patients and the hypoxia degree.
Further, when the end-tidal carbon dioxide (PETCO 2) value exceeds a preset value, the control data model is automatically switched into a secondary analysis control data model taking the end-tidal carbon dioxide (PETCO 2) value as a dominant part when the end-tidal carbon dioxide (PETCO 2) value is higher than a preset value, a flow correction interval of the end-tidal carbon dioxide (PETCO 2) value higher than 6KPa (45 mmHg) is automatically defined as 0.1L/min-2L/min, the intervention time is defined as 0.5min when the flow is reduced, and the increase flow is defined as 3 min; the flow correction gradient is 0.5L/min; the flow correction interval of end-tidal carbon dioxide (PETCO 2) lower than 4kPa (30 n1 mHg) is automatically defined to be 3L/min-4L/min, the flow is reduced according to 3min definition, the flow is increased according to 0.5min definition, and the flow correction gradient is 1L/min.
Furthermore, the data model analysis control unit writes common oxygen treatment schemes of different hypoxia types and mixed hypoxia types into the control data model, and medical staff only needs to set and select a reasonable oxygen treatment scheme, initial oxygen flow and oxygen treatment duration on a human-computer interaction interface, and the data model analysis control unit automatically gives out other factors such as a recommended blood oxygen saturation interval value, an oxygen inhalation flow correction interval value and the like for the medical staff to select and apply; of course, according to individual differences of patients, medical staff can modify specific parameters such as oxygen inhalation flow values, oxygen inhalation time length and the like given by the data model analysis control unit at the human-computer interaction interface, and a more optimized and safer personalized treatment scheme is provided.
The beneficial effects of the invention are as follows: automatically displaying the hypoxia type on a human-computer interaction interface according to the characteristics of a patient to give a recommended oxygen therapy scheme, a blood oxygen saturation interval value and an oxygen inhalation flow correction interval value for medical staff to select and apply; when the disease state progresses, the invention automatically displays the current hypoxia type, whether carbon dioxide retention occurs or not, automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value and an oxygen inhalation flow correction interval, and the value is used for medical staff to select and apply; if the patient has microcirculation disturbance such as heart failure, myocardial infarction, shock and other low perfusion symptoms, medical staff can select a three-level oxygen therapy scheme on a human-computer interaction interface; after setting the doctor's advice flow value and the oxygen inhalation duration, the data model analysis control unit intelligently controls the oxygen therapy working state according to a pre-written data model, judges the current hypoxia type, automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value and an oxygen inhalation flow correction interval, monitors the matching state of a dynamic percutaneous blood oxygen saturation (tcs 02) value, a carbon dioxide end expiration (PETCO 2) interval value, a target percutaneous blood oxygen saturation (tcs 02) value and a target carbon dioxide end expiration (PETCO 2) interval value, and when the dynamic menstrual value deviates from the target value control interval value and reaches the intervention control time, the data model analysis control unit automatically judges the current hypoxia type and whether carbon dioxide retention risks exist; the method automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value, an absorption flow correction interval, a flow correction interval and an output flow, so that the dynamic percutaneous blood oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO 2) interval value, the percutaneous oxygen partial pressure (tcpO 2) interval value and the percutaneous carbon dioxide partial pressure (tcpCO 2) interval value of a patient are accurately controlled within a reasonable target percutaneous blood oxygen saturation (tcs 02) control interval value, and the effectiveness and safety of oxygen therapy are improved.
Drawings
FIG. 1 is a functional block diagram of the present invention;
fig. 2 is a block diagram of the operation of the present invention.
Detailed Description
Example 1: examples of "hypoxia type" are further incorporated in table 1 based on clinical practice.
The hypoxia type is defined as: 1. hypo-and hypo-tension hypoxia not accompanied with hypercapnia 2, hypo-and hypo-tension hypoxia not accompanied with hypercapnia 3, sexual hypoxia/circulatory hypoxia a, histologic hypoxia/circulatory hypoxia not accompanied with hypercapnia b, histologic hypoxia/circulatory hypoxia combined with hypo-and hypercapnia d, histologic hypoxia/circulatory hypoxia combined with hypo-and hypo-tension hypoxia not accompanied with hypercapnia 4, hematologic hypoxia 5, neonatal
According to clinical needs, the oxygen therapy scheme is set to 6 (4 subspecies) alternative therapy schemes, wherein the oxygen therapy can be started only by setting initial flow values and oxygen inhalation duration of the therapy scheme serial numbers (1) - (9).
(1) Hypo-tonic hypoxia is not accompanied by hypercarbonemia: for example, a normal oxygen inhalation patient such as cancer and an anesthesia recovery patient, the target percutaneous blood oxygen saturation (tcs 02) value of oxygen therapy is set to 96%, and the allowable deviation value is +1%; the oxygen inhalation flow rate correction interval value is set to be the medium flow rate
(2) Hypo-stretch hypoxia with hypercarbonemia: the target percutaneous blood oxygen saturation (tcs 02) value for oxygen therapy was set to 90% and the allowable deviation value was +1%; the oxygen inhalation flow rate correction interval value is set to be low flow rate
(3) Sexual/circulatory hypoxia
a. Tissue hypoxia (or circulatory hypoxia) is accompanied by hypercapnia: such as shock, cardiac dysfunction, cardiovascular and cerebrovascular accidents, the value was set to 92% and the allowable deviation value was +1%; the oxygen inhalation flow rate correction interval value is set to be low flow rate;
b. the value of the histological hypoxia (or circulatory hypoxia) is set to 92% and the allowable deviation value is +1%; the oxygen inhalation flow correction interval value is set as the medium flow;
c. tissue hypoxia (or circulatory hypoxia) combined with hypotonic hypoxia: with hypercarbonemia: such as shock, cardiac dysfunction, cardiovascular and cerebrovascular accidents, the value was set to 92% and the allowable deviation value was +1%; the oxygen inhalation flow rate correction interval value is set to be low flow rate
d. The value of the histological hypoxia (or circulatory hypoxia) and the hypo-stretch hypoxia without hypercapnia is set to 92% and the allowable deviation value is +1%; the oxygen inhalation flow correction interval value is set as the medium flow;
(4) Blood hypoxia: set to 96% and allowed deviation value to +1%; the oxygen inhalation flow rate correction interval value is set to be high flow rate;
(5) The target percutaneous blood oxygen saturation (tcs 02) value for neonatal oxygen therapy was set to 93% and the allowable deviation value was +1%;
(6) The target percutaneous blood oxygen saturation (tcs 02) value for oxygen therapy for patients with acute respiratory distress syndrome in a particular patient is set at 92% and the allowable deviation value is +1%; the oxygen inhalation flow rate correction interval value is set to be high flow rate;
2. initial flow value setting: the medical advice flow value of the anesthesia resuscitation patient is generally set between 3 and 4L/min, the medical advice flow value of the neonatal oxygen therapy is set between 0.5 and 1L/min, and the medical advice flow value of the neonatal oxygen therapy is set between 1 and 2L/min for patients with end-tidal carbon dioxide partial pressure higher than 6kpa (45 mmhg) or lower than 4.6kpa (35 mmhg), acute respiratory distress syndrome patients and patients with high-carbon-acid-blood-symptom risk patients.
3. Interventional control time definition:
(1) Reducing flow intervention control time: 3min, when the dynamic transcutaneous oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO 2) value exceed the target transcutaneous oxygen saturation (tcs 02) control interval value and remain stable for 3min, the oxygen output flow is reduced.
(2) Increasing the flow intervention control time: 1min, when the dynamic percutaneous oxygen saturation (tcs 02) value is lower than the target percutaneous oxygen saturation (tcs 02) control interval value and is stably maintained for 3min, the oxygen output flow rate is increased.
4. Flow correction gradient definition: in the oxygen flow correction interval, the whole gradient is 0.5L/min when the flow is reduced, and the gradient is 1L/min when the flow is increased, and one gradient is adjusted every time an intervention control time unit is reached until the upper limit or the lower limit of the oxygen flow correction interval is reached. When the end-tidal carbon dioxide (PETCO 2) value exceeds a preset value, the method is automatically switched to a secondary oxygen therapy scheme taking the end-tidal carbon dioxide (PETCO 2) value as the dominant one when the end-tidal carbon dioxide (PETCO 2) value is higher than 6kPa (45 mmhg) 1 or lower than 4kPa (30 n1 mHg) and the state is stably maintained for 1-5 min; when the flow rate correction interval is automatically defined as 0.1L/min-2L/min and the end-tidal carbon dioxide (PETCO 2) value is higher than 6kPa (45 mmhg) at the time of higher than 6kPa (45 mmhg), if the initial flow rate is in a medium flow rate or high flow rate area, the flow rate is reduced by 0.5L/0.5min, the flow rate gradient is adjusted to 2L/min, if the initial flow rate is in a low flow rate area, the flow rate is reduced by 0.5L/0.5min, the flow rate gradient is adjusted to 0.5L/min, when the end-tidal carbon dioxide partial pressure value is lower than 4.6kPa (35 mmhg) and the state is kept stable for 1-5 min, the intervention time is defined by 0.5min, the flow rate correction gradient is adjusted to the highest value of the interval, if the initial flow rate interval is in the low flow rate area, the automatic adjustment is in the medium flow rate area, when the percutaneous oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO 2) value are stable, if a patient is in the steady state, if the patient has a circulatory disturbance such as a circulatory shock, the initial flow rate is in the low flow rate area, the initial flow rate interval is selected to be the three-level, the automatic flow rate adjustment is in the low flow rate interval, the three-level is selected, the automatic flow rate adjustment is such that the condition is low, and the condition is manually adjusted to be
5. Oxygen flow correction interval: according to the doctor's advice flow value, three intervals are automatically matched: 0.1L-2L of low flow doctor's advice; 1 to 4 times of traditional Chinese medicine flow doctor advice; 1 to 8 times of high flow medical advice.
Table 1: the data model analyzes each construction element of the control unit and a specific parameter list.
Combining Table 1. Sup. St 2 The oxygen therapy regimen (1) with the target percutaneous blood oxygen saturation (tcs 02) set at 96% is further described. The human-computer interaction interface sets three parameters of 96% of target percutaneous blood oxygen saturation (tcs 02) value, 5L/min of high-flow oxygen inhalation and 5h of oxygen inhalation duration for the patient. The data model analysis control unit automatically defines a control interval value of target percutaneous blood oxygen saturation (tcs 02) between 95% and 97%, and an oxygen flow correction interval is automatically defined between 1L/min and 8L/min. Entering an oxygen therapy mode after setting, dynamically monitoring a dynamic percutaneous blood oxygen saturation (tcs 02) value of a patient by a percutaneous blood oxygen saturation (tcs 02) monitoring module, maintaining a medical advice flow value when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is stably kept between 95% and 97%, and giving an instruction for reducing the oxygen output flow by a control system when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient exceeds the upper limit of a target percutaneous blood oxygen saturation (tcs 02) control interval value by 97% and the duration reaches 3min, wherein the flow control valve automatically reduces the oxygen output, the gradient is reduced every time by 0.5L/min, and one gradient is reduced every 3min until the minimum value of an oxygen flow correction interval; if the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is lower than the lower limit of the target percutaneous blood oxygen saturation (tcs 02) control interval value by 95% and the duration reaches 1min, the control system gives an instruction for increasing the oxygen output flow within 0.5min, the flow regulating valve automatically regulates the oxygen output, the gradient is regulated every 1L/min, and one gradient is regulated every 0.5min until the oxygen flow is repairedMaximum value of positive interval. When the oxygen output is regulated to the maximum value or the minimum value, but the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient still deviates from the target percutaneous blood oxygen saturation (tcs 02) control interval value, the data model analysis control unit gives out warning information, and the warning information is prompted in a human-computer interaction interface or remotely transmitted to a clinical care terminal to prompt medical staff to perform manual intervention; when the end-tidal carbon dioxide (PETCO 2) value is higher than 6kpa (45 mmhg) 1, and the state is kept stable for 3min, the state is automatically switched into a secondary analysis control data model taking the end-tidal carbon dioxide (PETCO 2) value as a main component, the flow rate is reduced by 0.5L/0.5min in a high flow area due to the initial flow, the flow rate gradient is adjusted to 2L/min, and after the set oxygen inhalation time is 5h, the flow control valve is automatically closed, and the control system prompts the end of the oxygen therapy.
The drawings and the embodiments are only for illustrating the technical scheme of the present invention and are not limiting. While the invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents substituted for elements thereof without departing from the spirit and scope of the invention, and it is intended to cover in the appended claims the scope of the invention without any limitation to the scope of the invention.
TABLE 1
Claims (13)
1. An intelligent system for automatically providing an oxygen treatment scheme mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end expiration (PETCO 2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a human-computer interaction interface and a communication transmission unit, and is characterized in that: the data model analysis control unit is provided with a control data model, and analysis control data model construction elements comprise an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide end expiration (PETCO 2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient; the element specific data model is pre-placed into a data model analysis control unit, and a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide end expiration (PETCO 2) interval value, an initial flow value and an oxygen inhalation time length can be individually set on a human-computer interaction interface according to the state of a patient; the human-computer interaction interface at least comprises a target percutaneous blood oxygen saturation (tcs 02) setting key, a carbon dioxide end expiration (PETCO 2) value setting key, an oxygen inhalation time length setting key, a flow setting key, a low perfusion mode key and an oxygen therapy scheme selecting key;
the data model analysis control unit is internally provided with a three-level oxygen therapy scheme, wherein the three-level oxygen therapy scheme is started when the end-tidal carbon dioxide (PETCO 2) value is normal and the infusion is not low, the percutaneous oxygen saturation (tcs 02) monitoring unit continuously monitors the dynamic percutaneous oxygen saturation (tcs 02) value of a patient, the two-level oxygen therapy scheme is started when the end-tidal carbon dioxide value is abnormal and higher than 6kpa (45 mmhg), the end-tidal carbon dioxide (PETCO 2) monitoring unit continuously monitors the end-tidal carbon dioxide (PETCO 2) value of the patient, the three-level oxygen therapy scheme is started when the patient has low infusion symptoms, and the percutaneous oxygen saturation (tcs 02) monitoring unit and the end-tidal carbon dioxide (PETCO 2) monitoring unit doubly continuously monitor the dynamic percutaneous oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO 2) value of the patient;
wherein, a data model analysis control unit of a percutaneous blood oxygen saturation (tcs 02) monitoring unit and a carbon dioxide end expiration (PETCO 2) monitoring unit is established;
wherein the intervention time is calculated based on the stable time of the dynamic percutaneous blood oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO 2) interval value, when the dynamic percutaneous blood oxygen saturation (tcs 02) value exceeds the control interval value and the state is stably maintained for 1-5 min, the data model analysis control unit reduces the oxygen output flow, when the dynamic percutaneous blood oxygen saturation (tcs 02) value is lower than the target percutaneous blood oxygen saturation (tcs 02) control interval value and the state is stably maintained for 0.5-3 min, the data model analysis control unit increases the oxygen output flow, and when the end-tidal carbon dioxide (PETCO 2) interval value exceeds the control interval value and the state is stably maintained for 10min, the oxygen treatment scheme of the hypoxia-associated hypercarbonated blood disease is switched;
when the value of end-tidal carbon dioxide (PETCO 2) is normal, 4.6kpa (35 mmhg) is less than or equal to Petco2 and less than or equal to 6kpa (45 mmhg), the value of percutaneous blood oxygen saturation (tcs 02) is less than or equal to 94%, the system judges that the patient is hypo-stretch hypoxia and does not accompany hypercarbonated blood, a data model analysis control unit automatically matches a corresponding flow correction interval and blood oxygen saturation interval value according to a set initial flow value and a selected oxygen treatment scheme, and when the data model analysis control unit intervenes in automatic regulation of oxygen output flow, the upper limit and the lower limit of the output flow are strictly controlled in the flow correction interval, and the automatic regulation is not broken through;
when the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), the percutaneous blood oxygen saturation (tcs 02) value is less than or equal to 94%, and the state is stably maintained for 5min, the system judges that the patient is hypo-anoxia accompanied by hypercarbonemia, if the initial flow is in a medium flow area or a high flow area, the flow gradient is adjusted to 2L/min, if the initial flow is in a low flow area, the flow gradient is adjusted to 0.5L/min;
if the patient develops hypo-perfusion symptoms of microcirculation disturbance, a tertiary oxygen treatment scheme is manually selected:
a. if the percutaneous blood oxygen saturation (tcs 02) value is more than or equal to 90%, the carbon dioxide at end-of-expiration (PETCO 2) value is more than 6kpa (45 mmhg), whether the percutaneous blood oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia or circulatory hypoxia with hypercarbonated blood, and the flow correction interval is adjusted to be a low flow area;
b. during periods when the percutaneous blood oxygen saturation (tcs 02) value is stable to be more than 90% and the percutaneous blood oxygen saturation (tcs 2) value is stable to be less than 4.6kpa (35 mmhg) < carbon dioxide end expiration (PETCO 2) value is stable to be less than 6kpa (45 mmhg), the system automatically selects an oxygen treatment scheme of tissue hypoxia or circulatory hypoxia without hypercarbonated blood, and the flow correction interval is adjusted to be a medium flow area;
c. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the 4.6kpa (35 mmhg) < end-tidal carbon dioxide (PETCO 2) value is less than 6kpa (45 mmhg), the system automatically selects an oxygen treatment scheme of tissue hypoxia or circulatory hypoxia and hypo-stretch hypoxia without hypercarbonated blood, and the flow correction interval is adjusted to be a medium flow area;
d. when the percutaneous blood oxygen saturation (tcs 02) value is less than 90%, the end-tidal carbon dioxide (PETCO 2) value is more than 6kpa (45 mmhg), and the state is stably maintained for 1-5 min, the system automatically selects an oxygen treatment scheme flow correction interval of tissue hypoxia or cyclic hypoxia and hypotonic hypoxia with hypercarbonated blood, adjusts the flow correction interval to a low flow area or automatically restores the output flow value to an initial flow value which is originally set, the automatic intervention and adjustment of the output flow is stopped, the data model analysis control unit gives warning information to prompt medical staff to correct the oxygen treatment scheme, and the warning information is prompted on a man-machine interaction interface or remotely transmitted to a clinical monitoring terminal.
2. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: automatically displaying the current hypoxia type on a human-computer interaction interface, judging whether carbon dioxide retention exists, and giving an oxygen treatment scheme, a suggested blood oxygen saturation interval value and an oxygen inhalation flow correction interval value, wherein a reasonable oxygen treatment scheme is set and selected on the human-computer interaction interface; the flow correction interval is divided into three regulation intervals of a low flow area, a medium flow area and a high flow area, the flow correction interval value is arranged in the data model, and as long as the initial flow value is set on the human-computer interaction interface, a reasonable oxygen treatment scheme is selected, and the data model analysis control unit automatically matches the corresponding flow correction interval and the percutaneous blood oxygen saturation (tcs 02) interval value.
3. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: when the disease progresses, the adjustment suggestion of the oxygen therapy scheme can be automatically provided, and meanwhile, warning information is sent out to prompt medical staff to correct the oxygen therapy scheme, and the warning information is prompted on a human-computer interaction interface or remotely transmitted to a clinical monitoring terminal.
4. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the data model analysis control unit takes the personalized target percutaneous blood oxygen saturation (tcs 02) value, end-tidal carbon dioxide (PETCO 2) value and oxygen therapy scheme selection key as a three-stage control unit, the given target percutaneous blood oxygen saturation (tcs 02) value is provided with an allowable deviation value, and the allowable deviation value of the target percutaneous blood oxygen saturation (tcs 02) is as follows+1%～+Defined between 3%; the end-tidal carbon dioxide (PETCO 2) values given have interval values of 4.6kpa (35 mmhg) < end-tidal carbon dioxide (PETCO 2) values < 6kpa (45 mmhg).
5. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the intervention time is controlled to be set between 0 and 60 minutes.
6. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the data model analysis control unit is internally provided with a blood hypoxia mode, is set to be high-flow oxygen therapy, the doctor orders flow value is 5L/min-8L/min, the flow correction interval is defined to be 0.1L/min-8L/min, and the blood hypoxia and blood gas change is special, but the blood hypoxia and blood gas change is easy to judge clinically, and only a nursing staff needs to select the mode when the blood hypoxia and blood gas change treatment device is used.
7. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the data model analysis control unit is internally provided with a neonate mode, is set to be used for low-flow oxygen therapy, and is provided with a doctor advice flow value of 0.5L/min-2L/min, and a flow correction interval is defined to be 0.1L/min-2L/min.
8. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: when the end-tidal carbon dioxide (PETCO 2) value is lower than a critical value less than 4.6kpa (35 mmhg), gradient adjustment is carried out to the highest value of the interval flow, if the initial flow interval is a low flow area, automatic adjustment is carried out to a middle flow area, or automatic intervention adjustment output flow is stopped, a data model analysis control unit gives out warning information, a medical staff is prompted to correct an oxygen treatment scheme, and the warning information is prompted on a man-machine interaction interface or remotely transmitted to a clinical monitoring terminal.
9. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the flow correction interval is divided into three adjusting intervals of a low flow area, a medium flow area and a high flow area, and specifically comprises the following steps: the method comprises the steps of when low-flow oxygen treatment is carried out, doctor advice flow value is between 0.5L/min and 2L/min, flow correction interval is defined as 0.1L/min and 2L/min, doctor advice flow value is between 3L/min and 4L/min when medium-flow oxygen treatment is carried out, flow correction interval is defined as 0.1L/min and 4L/min, doctor advice flow value is between 5L/min and 8L/min when high-flow oxygen treatment is carried out, and flow correction interval is defined as 0.1L/min and 8L/min.
10. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the flow correction gradient is a flow value which is increased or decreased every time the flow adjustment is performed, and the flow correction gradient is defined as between 0.1L/min and 1L/min in a defined oxygen flow correction interval.
11. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: target percutaneous blood oxygen saturation (tcs 02) preset in control data model, allowable deviation value is+1, intervention time, definition according to 3min when reducing flow rate, definition according to 0.5min when increasing flow rate; the flow correction gradient is 0.5L/min; the target percutaneous blood oxygen saturation (tcs 02) value, the initial flow value and the oxygen treatment duration are in a human-computer interaction interface according to the individual difference of patients and the degree of hypoxiaAnd (5) setting the surface individualization.
12. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: when the end-tidal carbon dioxide (PETCO 2) value exceeds a preset value, the control data model is automatically switched into a secondary analysis control data model taking the end-tidal carbon dioxide (PETCO 2) value as a dominant part when the state is stably maintained for 1-5 min, the flow correction interval of the end-tidal carbon dioxide (PETCO 2) higher than 6kpa (45 mmhg) is automatically defined as 0.1L/min-2L/min, and the intervention time is defined as 0.5min when the flow is reduced and the flow is increased as 3 min; the flow correction gradient is 0.5L/min; the flow correction interval of end-tidal carbon dioxide (PETCO 2) lower than 4kPa (30 n1 mHg) is automatically defined to be 3L/min-4L/min, the flow is reduced according to 3min definition, the flow is increased according to 0.5min definition, and the flow correction gradient is 1L/min.
13. An intelligent system for automatically providing an oxygen therapy regimen as recited in claim 1, further characterized by: the data model analysis control unit writes common oxygen treatment schemes of different hypoxia types and mixed hypoxia types into a control data model, and medical staff only needs to set and select a reasonable oxygen treatment scheme, initial oxygen flow and oxygen treatment duration on a human-computer interaction interface, and the data model analysis control unit automatically gives a recommended blood oxygen saturation interval value and an oxygen inhalation flow correction interval value for the medical staff to select and apply; of course, according to individual differences of patients, medical staff can modify the oxygen inhalation flow value and the oxygen inhalation time length given by the data model analysis control unit at the human-computer interaction interface, and a more optimized and safe personalized treatment scheme is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958090.0A CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958090.0A CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111991662A CN111991662A (en) | 2020-11-27 |
| CN111991662B true CN111991662B (en) | 2023-08-15 |
Family
ID=73469988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010958090.0A Active CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991662B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115337025A (en) * | 2022-09-21 | 2022-11-15 | 广东省第二人民医院（广东省卫生应急医院） | Multi-bed remote measurement blood oxygen system with alarm function |
| CN116196522B (en) * | 2023-04-27 | 2023-07-18 | 首都医科大学宣武医院 | Respiration monitoring and adjusting system |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004000114A1 (en) * | 2002-06-20 | 2003-12-31 | University Of Florida | Perfusion monitor and system, including specifically configured oximeter probes and covers for oximeter probes |
| WO2004060443A2 (en) * | 2002-12-27 | 2004-07-22 | Scott Laboratories, Inc. | Apparatuses and methods for automatically assessing and monitoring a patient’s responsiveness |
| CN104826204A (en) * | 2015-05-05 | 2015-08-12 | 阮雪红 | Intelligent servo oxygen therapy control system |
| CN105194759A (en) * | 2014-06-11 | 2015-12-30 | 三峡大学 | Infusion monitoring system for medical infusion bottles |
| WO2018180706A1 (en) * | 2017-03-31 | 2018-10-04 | 帝人ファーマ株式会社 | Oxygen supply device and method for controlling same |
| CN108721745A (en) * | 2018-06-15 | 2018-11-02 | 上海市北站医院 | A kind of novel monitoring PETCO2 automatic controls oxygen supply concentration device |
| CN108744190A (en) * | 2018-04-08 | 2018-11-06 | 西安汇智医疗集团有限公司 | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little |
| CN110461397A (en) * | 2017-03-31 | 2019-11-15 | 帝人制药株式会社 | Oxygen therapy system |
| CN110520043A (en) * | 2016-12-05 | 2019-11-29 | 梅迪平斯公司 | The system and method for carrying out respiration measurement using breathing gas sample |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130060110A1 (en) * | 1997-01-27 | 2013-03-07 | Lawrence A. Lynn | System and method for automatic detection of a plurality of spo2 time series pattern types |
| US20110257550A1 (en) * | 2010-03-20 | 2011-10-20 | Jay Choi | Method and Apparatus for Continuous Monitoring of Exhaled Carbon Dioxide |
| US20150034082A1 (en) * | 2013-08-05 | 2015-02-05 | Covidien Lp | Oxygenation-ventilation methods and systems |
| EP3238768A1 (en) * | 2016-04-27 | 2017-11-01 | Linde Aktiengesellschaft | System and method for delivering oxygen and preventing hypercapnia |
| US11141553B2 (en) * | 2018-07-11 | 2021-10-12 | General Electric Company | Ventilation control system and method utilizing patient oxygen saturation |
-
2020
- 2020-09-14 CN CN202010958090.0A patent/CN111991662B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004000114A1 (en) * | 2002-06-20 | 2003-12-31 | University Of Florida | Perfusion monitor and system, including specifically configured oximeter probes and covers for oximeter probes |
| WO2004060443A2 (en) * | 2002-12-27 | 2004-07-22 | Scott Laboratories, Inc. | Apparatuses and methods for automatically assessing and monitoring a patient’s responsiveness |
| CN105194759A (en) * | 2014-06-11 | 2015-12-30 | 三峡大学 | Infusion monitoring system for medical infusion bottles |
| CN104826204A (en) * | 2015-05-05 | 2015-08-12 | 阮雪红 | Intelligent servo oxygen therapy control system |
| CN110520043A (en) * | 2016-12-05 | 2019-11-29 | 梅迪平斯公司 | The system and method for carrying out respiration measurement using breathing gas sample |
| WO2018180706A1 (en) * | 2017-03-31 | 2018-10-04 | 帝人ファーマ株式会社 | Oxygen supply device and method for controlling same |
| CN110461397A (en) * | 2017-03-31 | 2019-11-15 | 帝人制药株式会社 | Oxygen therapy system |
| CN108744190A (en) * | 2018-04-08 | 2018-11-06 | 西安汇智医疗集团有限公司 | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little |
| CN108721745A (en) * | 2018-06-15 | 2018-11-02 | 上海市北站医院 | A kind of novel monitoring PETCO2 automatic controls oxygen supply concentration device |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111991662A (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111991663B (en) | 3-linked intelligent system capable of automatically providing oxygen treatment scheme | |
| JP5016595B2 (en) | Apparatus and method for controlling inspiratory oxygen concentration | |
| CN111991662B (en) | Intelligent system for automatically providing oxygen treatment scheme | |
| US8554298B2 (en) | Medical ventilator with integrated oximeter data | |
| EP2611485B1 (en) | Ventilator apparatus and system for ventilation | |
| EP2539001B1 (en) | Spontaneous breathing trial manager | |
| US20220105288A1 (en) | Respiratory distress management apparatus, system and method | |
| EP2652654A1 (en) | Device for controlling the alarm limit of an alarm device | |
| CN108568018A (en) | A kind of intelligent controlling device and control method of target blood oxygen saturation | |
| CN108744190A (en) | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little | |
| US20080236581A1 (en) | Method in a patient ventilating system | |
| WO2021026881A1 (en) | Medical device and medical device system | |
| EP2923719A1 (en) | Medical intelligent ventilation system | |
| CN114949523A (en) | Intelligent breathing machine system with oxyhemoglobin saturation control function and control method | |
| CN107708778A (en) | heart failure therapy device | |
| CA3065825C (en) | Anesthesia assessment system and method for lung protective ventilation | |
| CN106955102A (en) | A kind of anesthesia in operating room nursing device | |
| AU2009200284B2 (en) | A weaning and decision support system | |
| JPS6185963A (en) | Method and apparatus for controlling carbon dioxide in blood | |
| Sen et al. | Anesthesia workstation versus intensive care ventilator in pediatric cardiac surgery, is there a difference | |
| CN213609092U (en) | Simple continuous positive airway pressure device during single lung ventilation | |
| WO2023004542A1 (en) | Medical ventilation device and ventilation control method therefor, and storage medium | |
| Neumann et al. | SmartCare®/PS The automated weaning protocol | |
| Jeganathan et al. | P015| Telemonitoring in users of long-term non-invasive ventilation: Feasibility and determining clinical limits | |
| Huang et al. | The Nursing Method and Effect of Sedation and Analgesia in Mechanically Ventilated Patients Were Analyzed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |